CJC-1295 + Ipamorelin Blend
GHRH analog (CJC-1295 no-DAC) + ghrelin receptor agonist (Ipamorelin) blend
- Class
- GH secretagogue blend
- Half-life
- Ipamorelin ~2h drives
- Route
- Subcutaneous (SubQ)
- Cadence
- Daily
- Evidence
- Human clinical trials
Overview
The combo most research-peptide vendors actually ship: CJC-1295 (no-DAC) and Ipamorelin reconstituted into one vial at a fixed ratio. The point isn't pharmacology — both compounds work independently — it's convenience. One draw, one injection, one calculation. For people running daily GH-secretagogue protocols, that matters.
Pharmacologically it behaves like the sum of its parts: CJC-1295 raises GH baseline via the GHRH receptor, Ipamorelin layers a discrete ghrelin-receptor pulse on top. Together you get a bigger, cleaner GH pulse than either alone, which is the whole reason this pairing became the standard 'GH stack'. See the individual compound entries for receptor-level mechanism + safety; this page covers what's specific to running them as one product.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Both component peptides carry the same fundamental risk: GH-axis amplification. Don't run if you have, or recently had, any cancer. Hard no for active growth-plate-open users (under 25).
- Stacked side-effect profile is the union of the two: water retention + carpal tunnel from CJC ceiling, occasional injection-site reactions from either. Not additive in severity — same effects, slightly bigger amplitude.
- Research-market product quality is highly variable. A 'CJC + Ipa blend' that's actually under-dosed CJC or contaminated peptide is the failure mode you should expect, not the exception.
+ 2 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching CJC-1295 + Ipamorelin Blend.
- IGF-1 (baseline + 6-8 weeks in)
- Fasting glucose (incretins can drift)
- Sleep quality (subjective — usually improves first)
- Body composition (DEXA if you have access, scale + tape if not)
- Carpal tunnel symptoms
Frequently asked questions
What is CJC-1295 + Ipamorelin Blend?
GHRH analog (CJC-1295 no-DAC) + ghrelin receptor agonist (Ipamorelin) blend. The combo most research-peptide vendors actually ship: CJC-1295 (no-DAC) and Ipamorelin reconstituted into one vial at a fixed ratio. The point isn't pharmacology — both compounds work independently — it's convenience. One draw, one injection, one calculation. For people running daily GH-secretagogue protocols, that matters.
How is CJC-1295 + Ipamorelin Blend administered?
Subcutaneous (SubQ), typically daily.
What is the half-life of CJC-1295 + Ipamorelin Blend?
Ipamorelin ~2h drives — CJC-1295 (no-DAC) ~30 min · Ipamorelin ~2 h. The Ipamorelin pulse paces the combined GH release window..
Is CJC-1295 + Ipamorelin Blend approved for human use?
CJC-1295 + Ipamorelin Blend is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for CJC-1295 + Ipamorelin Blend?
Evidence tier: Human clinical trials. No human RCT specifically on the BLEND — the data is on the components separately. Sivakumaran 2002 (CJC-1295) + Raun 1998 (Ipamorelin) are the foundational refs.
What is commonly monitored when researching CJC-1295 + Ipamorelin Blend?
Commonly tracked markers + signals: IGF-1 (baseline + 6-8 weeks in), Fasting glucose (incretins can drift), Sleep quality (subjective — usually improves first), Body composition (DEXA if you have access, scale + tape if not), Carpal tunnel symptoms.
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.